Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - H.C. Wainwright has reiterated its Buy rating and $10.00 price target on Gossamer Bio Inc . (NASDAQ:GOSS) ahead of key clinical data expected in early 2026. The stock, currently trading at $1.99, has shown strong momentum with a 40% gain over the past six months, though InvestingPro analysis indicates the company faces cash burn challenges.
The firm’s analysis follows a literature review of seralutinib, Gossamer’s investigational treatment for pulmonary arterial hypertension (PAH), which reinforced its positive outlook on the drug’s potential. With a market capitalization of $456 million and analyst targets ranging from $1.25 to $15, the stock shows significant volatility with a beta of 1.96.
H.C. Wainwright highlighted data from the open-label extension following the Phase 2 TORREY trial, which demonstrated sustained hemodynamic and functional improvements through 72 weeks of treatment, including continued pulmonary vascular resistance reduction and improved six-minute walk distance among patients who remained on the drug.
The safety profile remained consistent with prior experience, with hepatic enzyme elevations and discontinuation rates comparable to those seen with other PAH therapies, according to the firm’s review of studies authored by leading PAH investigators.
The company’s Phase 3 PROSERA trial for seralutinib is expected to deliver top-line data in February 2026, with H.C. Wainwright expressing confidence in the drug’s potential as a "differentiated, disease-modifying therapy" for pulmonary indications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.